STADA Arzneimittel AG
https://www.stada.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From STADA Arzneimittel AG
And They’re Off! First Stelara Biosimilar Enters European Markets
Stada and Alvotech have heralded the start of biosimilar competition to Stelara in Europe with the launch of their partnered Uzpruvo version.
The View From The Top: European CEOs Highlight Industry Priorities
At a high-profile panel closing out Medicines for Europe’s 30th annual conference in Dublin, six industry leaders set out their views on key topics including pricing, regulation, sustainability, and stakeholder communication.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
Bio-Thera And Stada Joins Forces On Golimumab, With Up To $160m On The Table
With European biosimilar approvals already in hand for the immunology giants adalimumab and ustekinumab, Stada has allied with Bio-Thera Solutions to bring onboard the commercialization rights for the Chinese firm’s proposed golimumab biosimilar, which currently has a limited pool of chasers.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice